Disease · HP_0004936

Venous thrombosis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Venous thrombosis. Diseases, record HP_0004936. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0004936

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Venous thrombosis; Open Targets
Open Targets ID: HP_0004936; Open Targets
Other names: Blood clot in vein; Open Targets
NCI Thesaurus: C99107; NCI Thesaurus
Highest stage of its drugs: Approval, for 6 of its 21 drugs, from DailyMed, EMA Human Drugs and TTD; Open Targets

Drugs21

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
RIVAROXABAN	CHEMBL198362	Small molecule	Approval	EMA Human Drugs	8	7	7	Drugs and targets
HEPARIN	CHEMBL4650299	Oligosaccharide	Approval	TTD	2	1	1	Drugs and targets
FONDAPARINUX SODIUM	CHEMBL1200644	Oligosaccharide	Approval	EMA Human Drugs and TTD	3	0	0	Drugs and targets
HEPARIN SODIUM	CHEMBL1201657	Oligosaccharide	Approval	DailyMed	2	0	0	Drugs and targets
WARFARIN SODIUM	CHEMBL1200879	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
DESIRUDIN	CHEMBL1201662	Protein	Approval	EMA Human Drugs, at withdrawal	1	0	0	Drugs and targets
ATEZOLIZUMAB	CHEMBL3707227	Antibody	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
DABIGATRAN ETEXILATE	CHEMBL539697	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
ENOXAPARIN	CHEMBL1201685	Oligosaccharide	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 21

See all 21 drugs

Targets9

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
SERPINC1	Antithrombin-III	4	Antithrombin-III activator	Approval	https://conductscience.org/library/genes/462	Drugs and targets
F2	Prothrombin	3	Thrombin inhibitor	Approval	https://conductscience.org/library/genes/2147	Drugs and targets
F10	Coagulation factor X	2	Coagulation factor X inhibitor	Approval	https://conductscience.org/library/genes/2159	Drugs and targets
VKORC1	Vitamin K epoxide reductase complex subunit 1	2	Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor	Approval	https://conductscience.org/library/genes/79001	Drugs and targets
CD274	Programmed cell death 1 ligand 1	1	Programmed cell death 1 ligand 1 inhibitor	Phase 3	https://conductscience.org/library/genes/29126	Drugs and targets
HMGCR	3-hydroxy-3-methylglutaryl-coenzyme A reductase	1	HMG-CoA reductase inhibitor	Unknown	https://conductscience.org/library/genes/3156	Drugs and targets
PLAT	Tissue-type plasminogen activator	1	Tissue-type plasminogen activator exogenous protein	Phase 1	https://conductscience.org/library/genes/5327	Drugs and targets
PLG	Plasminogen	1	Plasminogen activator	Phase 3	https://conductscience.org/library/genes/5340	Drugs and targets
VEGFA	Vascular endothelial growth factor A, long form	1	Vascular endothelial growth factor A inhibitor	Phase 3	https://conductscience.org/library/genes/7422	Drugs and targets

Trials17

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01499953	Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux	Phase 3	472	2023-05-15	Superficial Vein Thrombosis	FONDAPARINUX, RIVAROXABAN	Open Targets' reading of its record	ClinicalTrials.gov
NCT01684423	Oral Rivaroxaban in Children With Venous Thrombosis	Phase 2	64	2017-09-21	Venous Thrombosis	RIVAROXABAN	Its record names the disease	ClinicalTrials.gov
NCT02309411	EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis	Phase 2	46	2018-06-13	Venous Thromboembolism	RIVAROXABAN	Its record names the disease	ClinicalTrials.gov
NCT02564718	Rivaroxaban for Treatment in Venous or Arterial Thrombosis in Neonates	Phase 1/2	10	2018-07-10	Thromboembolism	RIVAROXABAN	Its record names the disease	ClinicalTrials.gov
NCT03594045	Efficacy and Safety of Apixaban in the Treatment of Heparin Induced Thrombocytopenia (HIT)	Phase 2	5	2020-12-23	Heparin-induced Thrombocytopenia, Heparin-induced Thrombocytopenia and Thrombosis	APIXABAN	Open Targets' reading of its record	ClinicalTrials.gov
NCT03404635	Monotherapy Anticoagulation To Expedite Home Treatment of Venous Thromboembolism		1,300		Venous Thromboembolism	APIXABAN, RIVAROXABAN	Its record names the disease	ClinicalTrials.gov
NCT00691470	Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation	Phase 2/3	600		Atrial Fibrillation, Atrial Flutter, Venous Thromboembolic Disease, Myocardial Infarction, Cardiomyopathy	TECARFARIN SODIUM, WARFARIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT04649489	A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev	Phase 3	501		Venous Thrombosis	ATEZOLIZUMAB, BEVACIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT01613794	Rosuvastatin Use to Improve the Coagulation Profile in Patients With Venous Thrombosis	Not applicable	255		Deep Vein Thrombosis, Pulmonary Embolism	ROSUVASTATIN	Its record names the disease	ClinicalTrials.gov
NCT04345848	Preventing COVID-19 Complications With Low- and High-dose Anticoagulation	Phase 3	160		COVID, Sars-CoV2	ENOXAPARIN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 17

See all 17 trials

Comparisons in its trials9

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Rivaroxaban vs Fondaparinux: Major Bleeding (Main Safety Outcome)	0 of 236	0 of 235	471	NCT01499953	Trial comparisons
Fondaparinux vs Rivaroxaban: deaths from any cause	0 of 235	1 of 236	471	NCT01499953	Trial comparisons
Fondaparinux vs Rivaroxaban: serious adverse events	3 of 235	7 of 236	471	NCT01499953	Trial comparisons
Rivaroxaban vs Fondaparinux: Rate of Objectively Confirmed VTE Complications	7 of 211	4 of 224	435	NCT01499953	Trial comparisons
Rivaroxaban vs Fondaparinux: Rates of Surgery for SVT	0 of 211	2 of 224	435	NCT01499953	Trial comparisons
Rivaroxaban vs Fondaparinux: Composite Primary Efficacy Outcome	15 of 211	15 of 224	435	NCT01499953	Trial comparisons
Rivaroxaban, Suspension, BID, Age: 2-6 Years vs Rivaroxaban Suspension, BID, Age: 6 Months-2 Years: Number of Subjects With Symptomatic Recurrent Venous Thromboembolism	0 of 25	0 of 15	40	NCT02309411	Trial comparisons
Rivaroxaban (BAY59-7939) Suspension Bid vs Rivaroxaban (BAY59-7939) Suspension Tid: deaths from any cause	0 of 5	0 of 5	10	NCT02564718	Trial comparisons
Rivaroxaban (BAY59-7939) Suspension Bid vs Rivaroxaban (BAY59-7939) Suspension Tid: serious adverse events	0 of 5	1 of 5	10	NCT02564718	Trial comparisons

Papers from its trials16

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
21416132	RESULT	1	PubMed
19738134	RESULT	1	PubMed
42624156	DERIVED	1	PubMed
37675613	DERIVED	1	PubMed
35244208	DERIVED	1	PubMed
34953155	DERIVED	1	PubMed
34148351	DERIVED	1	PubMed
33502773	DERIVED	1	PubMed
33368114	DERIVED	1	PubMed
32407672	DERIVED	1	PubMed

1 to 10 of 16

See all 16 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/HP_0004936

GET https://conductscience.org/api/diseases/v1/HP_0004936/drugs?page=2

API reference For AI assistants